Researchers have identified distinct subtypes of myalgic encephalomyelitis (ME/CFS – also referred to as chronic fatigue syndrome) and there is renewed hope that treatments are available for this debilitating neurological illness.
One of these researchers is Dr A. Martin Lerner from Michigan, USA who will be revealing his ground breaking data from observations over the last seven years at the forthcoming International ME/CFS Conference 2008 in Westminster, London, on 23rd May.
Dr Lerner’s research indicates that specific long-term anti-herpesvirus pharmacokinetic administration of the drug valacyclovir/valganciclovir provides long-term significant benefit to one group of ME/CFS patients. Dr Lerner has identified two specific groups of patients; one with Herpesvirus Illness (EBV, HHV6, HCMV) with no co-infections and another Herpesvirus Illness with co-infections such as Lyme Disease, Babesiosis, Adult Rheumatic Fever and Mycoplasma Pneomoniae Myocarditis. Dr Lerner is the most experienced ME/CFS doctor in the world with long-term experience of treating an identified subset of patients with antivirals and has over twenty years of experience studying ME/CFS. He will be presenting his extensive data at the London conference, organised by the charity Invest in ME.
The theme of the conference is Sub Grouping of and Treatments for ME/CFS and the conference is changing the view that ME/CFS can be treated with a one-size-fits-all approach to treatment which the government and the National Institute for Clinical Excellence (NICE) have been advocating until now.
There is growing evidence of different subtypes and viral involvement in ME/CFS and the conference has aroused interest from the Chief Medical Officer and the UK Medical Research Council, both of which will be represented at the conference.
Other speakers at the conference include Dr Jonathan Kerr from St George’s University, London who has recently published a study identifying seven different genomic subtypes of ME/CFS and Dr John Chia, an infectious disease specialist from California, USA, who has is investigating antiviral treatments against enteroviruses as his recently published research showed that 135 out of 165 (82%) patients had stomach biopsy results that stained positive for enterovirus antigens compared with 7/ 34 (20%) of controls.
Dr Judy Mikovits, research director from the unique Whittemore Peterson Institute (WPI) in Nevada, USA will also be talking about the institute’s future plans for research and will be presenting data on a distinct subgroup of patients that is characterized by a significantly increased incidence of the development of Non-Hodgkins Lymphoma (NHL).Myalgic Encephalomyelitis (ME/CFS) is defined by the World Health Organisation as a neurological illness (code WHO-ICD-10-G93.3). With an estimated 250,000 sufferers of ME/CFS in the UK alone, of which 60,000 (one quarter of the people) are severely affected, many of them children, the illness is thought to cost the UK economy over £6 billion per year. Little public funding of biomedical research is currently provided by the government.
In its most extreme form it can leave sufferers bedridden and can even be fatal.It is hoped that the conference, bringing to an end ME Awareness Month, will kick-start publicly funded biomedical research into ME/CFS based on a more relevant and scientific approach to diagnosis and treatment of the illness.
Details of the CPD accredited conference may be found at – www.investinme.org
Kathleen McCall | alfa
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences